Podcast Summary: The Rundown

Episode: Deep Dive: Is Medline the Costco of Healthcare? Inside the Biggest IPO of 2025
Host: Zaid Admani
Date: December 20, 2025
Duration: ~10 minutes

Overview of the Episode's Main Theme

This episode of The Rundown provides a deep dive into Medline, a major medical equipment company that staged the largest IPO of 2025. Host Zaid Admani explores how Medline, once largely unknown outside medical circles, became a market leader with a business model often compared to Costco. The episode covers Medline’s company history, business moat, financials, IPO details, bullish arguments, and notable risks facing the newly-public business.

Key Discussion Points and Insights

1. Medline’s Path to the Largest 2025 IPO

• Medline, founded in 1966 by Jim and John Mills, has operated in the medical supply space for nearly 60 years ([00:40]).
• First IPO in 1972, then taken private by the Mills family due to their distaste for public markets.
• In 2021, the Mills family sold 79% of Medline to private equity for $34 billion, increasing company debt ([01:30]).
• Major private equity firms (BlackRock, Carlisle, others) later took Medline public in 2025, raising $6.3 billion at $29/share. The stock soared 40% on opening day, reaching a $50B+ market cap ([01:50]).
• Only five U.S. companies in the past decade have raised more than $5B in an IPO.

2. Business Model: The “Costco of Healthcare”

• Medline CEO Jim Boyle on CNBC:

  “My aspiration is to be the Costco of healthcare… Medline has a prime vendor model that both the vendor community and our customers pay to be a member of. They have a Kirkland brand that drives savings in value for their membership… We have the Medline brand that does the exact same thing.” ([03:04])

• Medline features:

  • Private-label Medline brand (like Costco’s Kirkland): 49% of 2024 revenue comes from these products, which have higher margins ([03:32]).
  • Vertical integration: 33 manufacturing facilities, 69 distribution centers, and 2,000 trucks for fast, next-day deliveries to 95% of U.S. hospitals.
  • Supply chain services: Medline acts as a one-stop shop, supplying both self-manufactured and third-party products and offering hospital supply chain optimization.

3. Why Are Investors Excited?

• Consistent Revenue Growth:
  • 50 consecutive years of annual revenue growth at an 18% CAGR ([04:50]).
  • Proven resilience: Revenue grew 17% during 2008–09 financial crisis and 11% yearly during COVID-19 ([05:15]).
• Customer Loyalty:
  • 98% retention rate — once a hospital switches, it rarely leaves ([05:35]).
• Demographic Tailwind:
  • U.S. population aged 65+ to increase 47% between 2022–2050 ([06:05]).
  • 60% of Americans have one or more chronic conditions, driving long-term demand ([06:12]).
• Healthcare Spend:
  • National health expenditures projected to outpace GDP growth at 5.6% annually through 2032 (CMS projection, [06:30]).

4. Risks and Headwinds for Medline

• Debt Load:
  • The 2021 buyout saddled Medline with significant debt. Even after paying $4B down from IPO proceeds, $12B+ in debt remains ([07:00]).
• Low Margins:
  • Operating margin is only 8–9% due to commoditized products ([07:27]).
• Tariffs:
  • Reliance on overseas manufacturing means U.S. tariffs could cut profits by $325–$375M in 2025 and $150–$200M in 2026 ([07:51]).
• Growth Rate Deceleration:
  • Medline’s growth has slipped below 10% in recent years ([08:12]).

Notable Quotes and Memorable Moments

• On the Business Model:

  "My aspiration is to be the Costco of healthcare... We have the Medline brand that does the exact same thing [as Kirkland]."
  — Jim Boyle, CEO, ([03:04])

• On Industry Dominance:

  "Once a hospital or medical facility switches to Medline, they basically never leave." ([05:35])
  — Zaid Admani

• On Concerns:

  “The debt load, the lack of upside, not to mention the lack of dividends, it just doesn’t get me excited, especially when you look at the 2026 IPO calendar.” ([08:45])
  — Zaid Admani

Timestamps for Key Segments

• [00:00-01:40] – Medline company history and journey to IPO
• [01:40-02:30] – Details of 2025 IPO and market reaction
• [03:04-03:32] – CEO’s “Costco of Healthcare” analogy
• [03:33-04:35] – Business model basics: private brands, supply chain integration
• [04:35-05:35] – Revenue growth statistics and “recession-proof” qualities
• [06:00-06:40] – Demographic drivers and healthcare spending outlook
• [07:00-08:00] – Debt, margins, tariffs, and other risks
• [08:30-09:30] – Host’s take and investment perspective

Summary Table: Medline’s Bull and Bear Cases

| Bullish Factors | Bearish Factors | |--------------------------------------------|----------------------------------------------| | 50 years of consistent revenue growth | High debt load from 2021 buyout | | 98% customer retention | Low margins (8–9%) | | Vertical integration & logistics moat | Growth trending below 10% | | Growing healthcare demand | Tariffs could depress profits | | Largest, fastest hospital supplier | Limited upside, no dividend |

Conclusion & Host’s Take

Zaid Admani closes with a personal note: while Medline is a compelling, “boring but great” business with enduring strengths and a formidable supply chain, the heavy debt, slim margins, and lack of explosive upside make it less appealing for risk-seeking investors, especially with anticipated tech IPOs on the horizon.

For those wanting a quick but thorough update on Medline and its IPO, this Deep Dive delivers clarity on why a “boring” business can generate huge Wall Street excitement—and why that might (or might not) translate into a smart investment.